VALUE OF EARLY LUSPATERCEPT USE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES
D Valcárcela, A Coughlanb, SL Klijnc, B Whited, C Franco-Villalobose, A Sichevayaf, D Mitevag, A Hnooshh, EM Cavalcantei, A Yucelc
a Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain
b Evidera, Bethesda, United States
c Bristol Myers Squibb (BMS), Princeton, United States
d Evidera, San Francisco, United States
e Evidera, Montreal, Quebec, Canada
f Evidera, London, United Kingdom
g Celgene International Sàrl, a Bristol-Myers Squibb (BMS) Company, Boudry, Switzerland
h Bristol Myers Squibb (BMS), Uxbridge, United Kingdom
i Bristol Myers Squibb (BMS), São Paulo, Brazil
Ver másLido
330
Vezesque se leu este artigo
110
Total PDF
220
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 Maio | 38 | 9 | 47 |
| 2025 Abril | 32 | 14 | 46 |
| 2025 Março | 32 | 6 | 38 |
| 2025 Fevereiro | 35 | 13 | 48 |
| 2025 Janeiro | 14 | 10 | 24 |
| 2024 Dezembro | 21 | 8 | 29 |
| 2024 Novembro | 31 | 30 | 61 |
| 2024 Outubro | 17 | 20 | 37 |
